Inclusion Criteria:  Female or male patients >18 years of age at the time of consent. Unifocal BIRADS-5 or -6 lesions at the time of diagnostic imaging Unifocal, histologically-proven T0-T3, N0-1 invasive breast cancer at the time of mid-chemotherapy imaging if receiving neoadjuvant therapy  Exclusion criteria  Distant metastasis Inflammatory breast carcinoma Nickel allergy Patients with active cardiac implants Patients participating in Protocol 2016-0046, Multicenter Trial for Eliminating Breast Cancer Surgery in Exceptional Responders to Neoadjuvant Therapy Patients participating in Protocol AFT-25, Comparison of Operative to Monitoring and Endocrine Therapy for Low-risk DCIS (COMET)